These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 7060034)

  • 1. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
    Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
    Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
    Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet JD; Alexanian R; Salmon SE; Haut A; Dixon DO
    Cancer Treat Rep; 1984 Mar; 68(3):481-5. PubMed ID: 6200220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
    Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H
    Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Silver RT; Cooper MR; Henderson E; Kyle RA; Haurani FI; Cuttner J
    Cancer; 1982 Nov; 50(9):1669-75. PubMed ID: 7116299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
    Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Polychemotherapy in multiple myeloma. The COMPA protocol].
    Vázquez-Villegas V; Delgado Lamas JL; Romero-García F; Rodríguez-Carrillo J; Medina-Ruiz F
    Rev Invest Clin; 1989; 41(4):345-50. PubMed ID: 2698501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].
    Monti G; Cereda UG; Pessina E; De Micheli N; Grisetti GC; Invernizzi F
    Minerva Med; 1983 Feb; 74(5):155-63. PubMed ID: 6828250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
    Broun GO; Petruska PJ; Hiramoto RN; Cohen HJ
    Cancer Treat Rep; 1982 Feb; 66(2):237-42. PubMed ID: 7034931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
    Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
    J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple myeloma: results with the M-2 protocol in a community hospital.
    Miller S; Perrotta AL
    J Am Osteopath Assoc; 1979 Aug; 78(12):857-64. PubMed ID: 489428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.